In Vitro Diagnostics (IVD) Market - Global Growth by Manufacturers, Regions, Type and Application, Forecast to 2025


4 February 2020 - The global In Vitro Diagnostics (IVD) Market size is likely to reach USD 98.99 billion by 2025 and is anticipated to grow at a CAGR of 6.6% during the forecast period. In-Vitro diagnostics is an extensive range of veterinary and medical laboratory tests that are used to analyze diseases and constantly monitor the clinical status of patients using samples of blood, cells, or other tissues attained from a patient.

         

Considering its driving factors, the growing geriatric population that is very much susceptible to diseases, needs constant diagnostic tests. Additionally, technological expansions in terms of precision, compactness, and cost-effectiveness are helping the market to fast-track the demand for In-Vitro diagnostics industry in the current scenario.

View Full Report with TOC @ https://www.millioninsights.com/industry-reports/in-vitro-diagnostics-ivd-market

In addition to this, there is a continuous rise in the demand for Point-of-Care (PoC) devices and the improved technologies such as miniaturization of microfluidics, biochips, and nano-biotechnology are now being introduced, which are expected to boost the demand for PoC products. These improvements will eventually lead to an upsurge in the access to point-of-care diagnostic tests and are likely to facilitate rapid and effective test results and will aid the In-Vitro diagnostics market to experience massive growth during the forecast period.

The In Vitro diagnostics (IVD) industry is segmented on the basis of product & service (Reagents & Kits, Instruments, Fully-automated Instruments, Semi-automated Instruments, Others, Data Management Software, Services);

Technology segment comprises (Immunochemistry/Immunoassay (Enzyme-Linked Immunosorbent Assay (ELISA), Chemiluminescence Immunoassay (CLIA), Fluorescence Immunoassay (FIA), Colorimetric Immunoassay (CI), Radioimmunoassays (RIA), Rapid Tests,Western Blot, ELISPOT), Clinical Chemistry (Basic Metabolic Panel, Electrolyte Panel, Liver Panel, Lipid Profile, Renal Profile, Thyroid Function Panel, Specialty Chemicals), Molecular Diagnostics (Polymerase Chain Reaction (PCR), Isothermal Nucleic Acid Amplification Technology (INAAT), Hybridization (In-situ Hybridization & FISH), DNA Sequencing & NGS, Microarray, Others), Microbiology, Hematology, Coagulation & Hemostasis, Urinalysis, Others);

Application category includes (Diabetes, Infectious Diseases, Oncology/Cancer, Cardiology, Nephrology, Autoimmune Diseases, Drug Testing/Pharmacogenomics, HIV/AIDS, Others);

End user segmentation for In Vitro Diagnostics market includes (Laboratories (Large/Reference Laboratories, Medium-sized Laboratories, Small Laboratories), Hospitals, Academics, Point-Of-Care Testing, Patient Self-Testing, Others) and by region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa).

Based on product, reagents & kits dominated the In Vitro diagnostics industry and held the highest market share as the usage of IVD testing has increased. Along with this, taking the technology insights into consideration, clinical chemistry controlled the market by generating higher revenue.

Geographically, North America is expected to dominate the IVD market as it holds the largest market share owing to the availability of government funds, and increase in the usage of molecular diagnostics in cancer screening and genetic disorders. Followed by this, Asia Pacific is likely to command the highest growth rate during the estimated time span due to the rise in the number of hospitals and an increase in healthcare expenditure. In the near future In-Vitro diagnostics (IVD) industry will continue to come up with some extraordinary product innovations to attract new consumers and investors, for them to continue the domination.

Some of the prominent key players outlined in the In-Vitro diagnostics (IVD) market report are Cepheid, Siemens Healthineers, Qiagen, bioMerieux SA, Sysmex Corporation, Hologic, Inc. (Gen-Probe), F. Hoffmann-La Roche Ltd., Becton, Dickinson and Company, Hologic, Inc. (Gen-Probe), Abbott, Alere and Danaher. All the leading companies are including mergers and acquisitions, partnerships and joint ventures to enhance the growth of the market efficiently.

Market Segment:

In Vitro Diagnostics (IVD) Product Outlook (Revenue, USD Billion, 2014 - 2025)
    • Instruments
    • Reagents
    • Services

In Vitro Diagnostics (IVD) Technology Outlook (Revenue, USD Billion, 2014 - 2025)
    • Immunology
    • Hematology
    • Clinical chemistry
    • Molecular Diagnostics
    • Coagulation
    • Microbiology
    • Others

In Vitro Diagnostics (IVD) Application Outlook (Revenue, USD Billion, 2014 - 2025)
    • Infectious disease
    • Diabetes
    • Oncology
    • Cardiology
    • Nephrology
    • Autoimmune diseases
    • Drug testing
    • Others

In Vitro Diagnostics (IVD) End-Use Outlook (Revenue, USD Billion, 2014 - 2025)
    • Hospital
    • Laboratory
    • Home care
    • Others

In vitro Diagnostics (IVD) Regional Outlook (Revenue, USD Billion, 2014 - 2025)
    • North America
        • U.S.
        • Canada
    • Europe
        • Germany
        • U.K.
    • Asia Pacific
        • Japan
        • China
    • Latin America
        • Brazil
        • Mexico
    • Middle East & Africa
        • South Africa

Request Sample Copy of This Report @ https://www.millioninsights.com/industry-reports/in-vitro-diagnostics-ivd-market/request-sample



Location: Unnamed Road, 76597 Gernsbach, Germany

Comments

Post a Comment

Popular posts from this blog

Thermal Interface Materials Market Revenue, Share and Growth Rate to 2030

  The global thermal interface materials (TIMs) market size was estimated at USD 4.10 billion in 2024 and is projected to reach USD 7.89 billion by 2030, registering a strong CAGR of 11.6% from 2025 to 2030. Growth in this market is primarily driven by the increasing adoption of consumer electronics such as smartphones, laptops, gaming systems, and wearable devices, which require efficient heat dissipation to maintain performance. Similarly, the rising use of industrial automation technologies in developing economies, combined with the growing disposable income of the middle-class population, is significantly boosting demand for TIMs. These materials are specifically engineered to be applied between two hard surfaces often between electronic components and heat sinks to facilitate efficient heat conduction, ensuring safe operation even as devices become smaller, faster, and more powerful. The diverse commercial availability of TIMs in multiple formats, including grea...
Read more

Advancing Hydrogen Production Through Next Generation Electrolyzer Technologies

  Electrolyzers are at the center of the global transition toward clean energy and decarbonization. By using electricity to split water into hydrogen and oxygen, electrolyzers enable the production of green hydrogen when powered by renewable sources such as solar and wind. As governments and industries seek alternatives to fossil fuels, electrolyzer technology is rapidly evolving to deliver higher efficiency, scalability, and cost effectiveness. Hydrogen produced through electrolysis offers significant potential for decarbonizing hard to abate sectors including heavy industry, transportation, and power generation. Unlike conventional hydrogen production methods that rely on natural gas reforming, electrolyzers provide a pathway to low carbon hydrogen, supporting climate goals and long term energy security. Technology Advancement Across Electrolyzer Several electrolyzer technologies are currently shaping the industry, each offering distinct advantages. Alkaline electrol...
Read more

Drug Discovery Outsourcing Driving Faster Innovation and Smarter R&D Strategies

  Drug discovery outsourcing has emerged as a strategic approach for pharmaceutical and biotechnology companies seeking to enhance efficiency, reduce costs, and accelerate innovation. As therapeutic research becomes increasingly complex, organizations are turning to specialized external partners to manage critical aspects of the discovery pipeline. By leveraging advanced technologies, global expertise, and scalable infrastructure, outsourcing has become a cornerstone of modern drug development strategies. The early stages of drug development require significant investment in target identification, lead optimization, preclinical testing, and regulatory documentation. Managing these processes internally can strain resources and extend development timelines. Drug discovery outsourcing allows companies to access experienced scientific teams, state of the art laboratories, and advanced analytical tools without bearing the full burden of capital expenditure. Benefits of Out...
Read more